Non-Alcoholic Steatohepatitis Market H2 2015 Pipeline Therapeutics Assessment adds ‘Non-Alcoholic Steatohepatitis Pipeline Review, H2 2015’ Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.

This research provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Inquire before buying this research at: .

This research features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the research undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope for this research:

·         The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type

·         Latest news and deals relating related to pipeline products

Companies mentioned: AlbireoPharma, Aquinox Pharmaceuticals Inc., Ardelyx, Inc., Arisaph Pharmaceuticals, Inc., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cardax Pharmaceuticals, Inc., Cerenis Therapeutics Holding SA, Conatus Pharmaceuticals Inc., Connexios Life Sciences Pvt. Ltd., Daiichi Sankyo Company, Limited, Dr. Falk Pharma GmbH, DURECT Corporation, Dynavax Technologies Corporation, Enanta Pharmaceuticals, Inc., Exicure, Inc., Galectin Therapeutics, Inc., Galmed International Ltd., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., iCo Therapeutics Inc., Immuron Limited, Intercept Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Jenrin Discovery, Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Merck & Co., Inc., Mochida Pharmaceutical Co., Ltd., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, Nippon Chemiphar Co., Ltd., Novartis AG, Novo Nordisk A/S, ProMetic Life Sciences Inc., Protalix BioTherapeutics, Inc., Regulus Therapeutics Inc., RuiYi Inc., Shire Plc, Stelic Institute & Co., Therapix Biosciences Ltd, Tobira Therapeutics, Inc., Vascular Biogenics Ltd., Verva Pharmaceuticals Limited, Viking Therapeutics, Inc., Virobay Inc., Zafgen Inc. and Zydus Cadila Healthcare Limited

Complete research on H2 Pipeline Review of ‘Non-Alcoholic Steatohepatitis’ spread across 285 pages at .

Reasons to buy this research:

·         Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

·         Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

·         Develop strategic initiatives by understanding the focus areas of leading companies

·         Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis

·         Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

·         Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics

·         Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

·         Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline